Merck has issued a letter to healthcare professionals letting them know that Nasonex (mometasone furoate monohydrate) Nasal Spray 50mcg is currently out of stock due to a manufacturing issue. The company anticipates having supply available by either November or December of this year.

RELATED: Sublingual Birch Pollen Preparation Improves Allergy Scores in Study

Nasonex is indicated for the treatment of seasonal and perennial allergic rhinitis symptoms in patients ≥2yrs of age and for the prophylaxis of seasonal allergic rhinitis symptoms in patients ≥12yrs of age. It is also approved for the treatment of nasal polyps in patients aged ≥18 years.

For more information visit